Antagonists of interleukin-15
AssigneeImmuner Corp.
InventorsKenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
Life of this patent
Estimating the term…
Abstract
Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the β- or γ-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
Claims18
A method for reducing IL-15 activity in a mammal in need of such treatment comprising administering an antagonist of IL-15 activity that prevents IL-15 from transducing a signal through either of the β- or γ-subunits of the Il-15 receptor complex, wherein the antagonist is a monoclonal antibody against IL-15 that interferes with binding of (i) amino acid Asp56 of the IL-15 molecule to the β-subunit of the IL-15 receptor complex or (ii) amino acid Gln156 of the IL-15 molecule to the γ-subunit of the IL-15 receptor complex.
Dependencies are inferred from the claim text.